Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment

Health and Quality of Life Outcomes

Volumn 10, Issue , 2012, Pages

  Revicki, Dennis A ^a   van den Eertwegh, Alfons J M ^b   Lorigan, Paul ^c   Lebbe, Celeste ^d   Linette, Gerald ^e   Ottensmeier, Christian H ^f   Safikhani, Shima ^a   Messina, Marianne ^g   Hoos, Axel ^g   Wagner, Samuel ^g   Kotapati, Srividya ^g  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d SAINT LOUIS HOSPITAL   (France)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^g BRISTOL MYERS SQUIBB   (United States)

Author keywords

Advanced melanoma; EORTC QLQ C30; Health related quality of life; Ipilimumab; Randomized clinical trial

Indexed keywords

GLYCOPROTEIN GP 100; IPILIMUMAB; MONTANIDE ISA 51; PEPTIDE VACCINE; PLACEBO; ANTINEOPLASTIC AGENT; CANCER VACCINE; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; COGNITION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPNEA; EMOTIONALITY; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FATIGUE; FEMALE; FUNCTIONAL STATUS; HEALTH STATUS; HUMAN; INDUCTION CHEMOTHERAPY; INOPERABLE CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; PAIN; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RANDOMIZED CONTROLLED TRIAL; SOCIAL STATUS; SYMPTOMATOLOGY; TREATMENT OUTCOME; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HEALTH STATUS INDICATOR; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PSYCHOLOGICAL ASPECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; QUALITY OF LIFE;

EID: 84862172613     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-10-66     Document Type: Article

References (47)

1. American Cancer Society, Atlanta Cancer Facts & Figures 2010 2010, American Cancer Society, Atlanta, 3421472, 22904645, American Cancer Society, Atlanta.
2. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012. 10.1056/NEJMra041245, 15342808.
3. Bedikian AY, Millward M, Pehamberger H, Conry R, Gore M, Trefzer U, Pavlick AC, DeConti R, Hersh EM, Hersey P, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745. 10.1200/JCO.2006.06.0483, 16966688.
4. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
5. Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-166.
6. Korn EL, Liu PY, Lee SJ, Chapman JA, Niedzwiecki D, Suman VJ, Moon J, Sondak VK, Atkins MB, Eisenhauer EA, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26:527-534. 10.1200/JCO.2007.12.7837, 18235113.
7. Cornish D, Holterhues C, van de Poll-Franse LV, Coebergh JW, Nijsten T. A systematic review of health-related quality of life in cutaneous melanoma. Ann Oncol 2009, 20(suppl 6):vi51-vi58. 10.1093/annonc/mdp255, 2712593, 19617298.
8. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
9. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 20525992.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 21639808.
11. Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm 2008, 65(suppl 9):S3-S8.
12. Robert C, Thomas L, Bondarenko I, O'Day S, DJ M, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526. 10.1056/NEJMoa1104621, 21639810.
13. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012, 366:707-714. 10.1056/NEJMoa1112302, 22356324.
14. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125. 10.1200/JCO.2004.04.165, 15020614.
15. Patel P, Suciu S, Mortier L, Kruit W, Robert C, Schadendorf D, Keilholz E, Musat A, Eggermont A, . Spatz Extended schedule, escalated dose temozlomide versus dacarbazine in stage IV malignant melanoma: final results of the randomised phase III study (EORTC 18032). Ann Oncol 2008, 19. Abstract LB8, Spatz.
16. Ribas A, Hauschild A, Kefford R, Gomez-Navarro J, Pavlov D, Marshall MA. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 2008, 26. Abstract LBA9011.
17. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993, 85:622-632. 10.1093/jnci/85.8.622, 8468720.
18. Sparano JA, Fisher RI, Sunderland M, Margolin K, Ernest ML, Sznol M, Atkins MB, Dutcher JP, Micetich KC, Weiss GR, et al. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol 1993, 11:1969-1977.
19. Guidance for industry on clinical trial endpoints for the approval of cancer drugs and biologics. Fed Regist 2007, 72:27575-27576.
20. Trask PC, Paterson AG, Esper P, Pau J, Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004, 13:526-536. 10.1002/pon.770, 15295774.
21. Boyle DA. Psychological adjustment to the melanoma experience. Semin Oncol Nurs 2003, 19:70-77. 10.1053/sonu.2003.50006, 12638383.
22. Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of psychological distress by cancer site. Psychooncology 2001, 10:19-28. 10.1002/1099-1611(200101/02)10:1<19::AID-PON501>3.0.CO;2-6, 11180574.
23. Derogatis LR, Morrow GR, Fetting J, Penman D, Piasetsky S, Schmale AM, Henrichs M, Carnicke CL. The prevalence of psychiatric disorders among cancer patients. JAMA 1983, 249:751-757. 10.1001/jama.1983.03330300035030, 6823028.
24. Vurnek M, Buljan M, Situm M. Psychological status and coping with illness in patients with malignant melanoma. Coll Antropol 2007, 31(Suppl 1):53-56.
25. Cohen L, Parker PA, Sterner J, De Moor C. Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumour-derived vaccine. Melanoma Res 2002, 12:505-511. 10.1097/00008390-200209000-00013, 12394193.
26. Bender CM, Yasko JM, Kirkwood JM, Ryan C, Dunbar-Jacob J, Zullo T. Cognitive function and quality of life in interferon therapy for melanoma. Clin Nurs Res 2000, 9:352-363. 10.1177/10547730022158537, 11276624.
27. Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010, 9:142-157. 10.1177/1534735410369673, 20483874.
28. Cashin RP, Lui P, Machado M, Hemels ME, Corey-Lisle PK, Einarson TR. Advanced cutaneous malignant melanoma: a systematic review of economic and quality-of-life studies. Value Health 2008, 11:259-271. 10.1111/j.1524-4733.2007.00243.x, 18380638.
29. Cormier JN, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Camacho LH, Kim K, Webster K, Cella D, Palmer JL. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer 2008, 112:2249-2257. 10.1002/cncr.23424, 18383513.
30. Quirt I, Verma S, Petrella T, Bak K, Charette M. Temozolomide for the treatment of metastatic melanoma: a systematic review. Oncologist 2007, 12:1114-1123. 10.1634/theoncologist.12-9-1114, 17914081.
31. Paterson AG, Trask PC, Wagner LI, Esper P, Redman B. Validation of the FACT-BRM with interferon-alpha treated melanoma patients. Qual Life Res 2005, 14:133-139. 10.1007/s11136-004-1694-x, 15789947.
32. Kiebert GM, Jonas DL, Middleton MR. Health-related quality of life in patients with advanced metastatic melanoma: results of a randomized phase III study comparing temozolomide with dacarbazine. Cancer Invest 2003, 21:821-829. 10.1081/CNV-120025084, 14735685.
33. Young AM, Marsden J, Goodman A, Burton A, Dunn JA. Prospective randomized comparison of dacarbazine (DTIC) versus DTIC plus interferon-alpha (IFN-alpha) in metastatic melanoma. Clin Oncol (R Coll Radiol) 2001, 13:458-465.
34. Sigurdardottir V, Bolund C, Sullivan M. Quality of life evaluation by the EORTC questionnaire technique in patients with generalized malignant melanoma on chemotherapy. Acta Oncol 1996, 35:149-158.
35. Chiarion-Sileni V, Del Bianco P, De Salvo GL, Lo Re G, Romanini A, Labianca R, Nortilli R, Corgna E, Dalla Palma M, Lo Presti G, Ridolfi R. Quality of life evaluation in a randomised trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 2003, 39:1577-1585. 10.1016/S0959-8049(03)00372-1, 12855265.
36. Beusterien KM, Ackerman SJ, Plante K, Glaspy J, Naredi P, Wood D, Gehlsen K, Agarwala SS. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer 2003, 11:304-312.
37. Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat Med 1997, 16:1197-1209. 10.1002/(SICI)1097-0258(19970615)16:11<1197::AID-SIM531>3.0.CO;2-9, 9194267.
38. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010, 11:155-164. 10.1016/S1470-2045(09)70334-1, 20004617.
39. Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 2007, 12:864-872. 10.1634/theoncologist.12-7-864, 17673617.
40. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009, 58:823-830. 10.1007/s00262-008-0653-8, 19198837.
41. European Organisation for Research and Treatment of Cancer European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) , European Organisation for Research and Treatment of Cancer, Brussels, [cited 2012 May]; Available from: http://groups.eortc.be/qol/questionnaires_qlqc30.htm, European Organisation for Research and Treatment of Cancer.
42. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376. 10.1093/jnci/85.5.365, 8433390.
43. Osoba D, Aaronson N, Zee B, Sprangers M, te Velde A. Modification of the EORTC QLQ-C30 (version 2.0) based on content validity and reliability testing in large samples of patients with cancer. The Study Group on Quality of Life of the EORTC and the Symptom Control and Quality of Life Committees of the NCI of Canada Clinical Trials Group. Qual Life Res 1997, 6:103-108.
44. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16:139-144.
45. Lipscomb J, Reeve BB, Clauser SB, Abrams JS, Bruner DW, Burke LB, Denicoff AM, Ganz PA, Gondek K, Minasian LM, et al. Patient-reported outcomes assessment in cancer trials: taking stock, moving forward. J Clin Oncol 2007, 25:5133-5140. 10.1200/JCO.2007.12.4644, 17991933.
46. Lichtman SM. Guidelines for the treatment of elderly cancer patients. Cancer Control 2003, 10:445-453.
47. Testori A, Soteldo J, Sances D, Mazzarol G, Trifiro G, Zonta M, Rastrelli M, Schenone F, Verrecchia F. Cutaneous melanoma in the elderly. Melanoma Res 2009, 19:125-134. 10.1097/CMR.0b013e328329fe95, 19381113.